| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H17ClN2OS |
| Molecular Weight | 320.837 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC=CC2=C1SC(=C2)C(=O)N[C@H]3CN4CCC3CC4
InChI
InChIKey=SSRDSYXGYPJKRR-ZDUSSCGKSA-N
InChI=1S/C16H17ClN2OS/c17-12-3-1-2-11-8-14(21-15(11)12)16(20)18-13-9-19-6-4-10(13)5-7-19/h1-3,8,10,13H,4-7,9H2,(H,18,20)/t13-/m0/s1
| Molecular Formula | C16H17ClN2OS |
| Molecular Weight | 320.837 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Encenicline (EVP-6124; MT-4666) acts as a potent partial and selective agonist at alpha-7 nicotinic acetylcholine receptor. Encenicline significantly improved memory function in animal models. FORUM Pharmaceuticals (formerly EnVivo Pharmaceuticals) is developing encenicline for the treatment of cognition disorders such as schizophrenia and for Alzheimer's disease.
CNS Activity
Originator
Approval Year
AUC
Sourcing
PubMed
Patents
Sample Use Guides
Encenicline was well tolerated at single doses up to 180 mg, and doses as low as 1 mg had dose- and time-dependent pharmacodynamic effects on the central nervous system.
Results from a phase IIb trial showed that encenicline (2.0mg once daily) significantly improved cognition and clinical function in patients with mild-to-moderate Alzheimer's disease.
Route of Administration:
Oral
|
|
TARGET -> AGONIST |
|
||
|
|
SALT/SOLVATE -> PARENT |
Showing 1 to 2 of 2 entries
